Strike 3 Finishes Nexavar's 'MISSION' in Phase III NSCLC
By Marie Powers
Wednesday, May 23, 2012
To almost no one's surprise, another potential treatment in non-small-cell lung cancer (NSCLC) bit the dust as Nexavar (sorafenib) failed to meet the primary endpoint of improving overall survival (OS) in the Phase III MISSION (Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer) trial in patients with advanced relapsed or refractory nonsquamous disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.